Eris Lifesciences Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

13.60

13.59

13.58

13.58

13.75

Share application money

-

0.45

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

2,208.29

1,904.51

1,561.89

1,286.12

1,142.26

Loan funds

Secured loans

316.87

-

-

-

-

Unsecured loans

-

-

-

-

-

Total

2,538.76

1,918.56

1,575.47

1,299.70

1,156.01

Uses of funds

Fixed assets

Gross block

976.89

708.68

662.73

669.50

536.14

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

79.07

66.68

78.41

68.86

52.29

Net block

897.81

642.00

584.32

600.64

483.85

Capital work-in-progress

0.34

2.98

1.56

4.37

2.73

Investments

996.52

777.72

531.37

320.30

580.47

Net current assets

Current assets, loans & advances

888.98

727.71

637.56

557.81

403.33

Less : current liabilities & provisions

244.90

231.86

179.34

183.43

314.37

Total net current assets

644.08

495.85

458.22

374.39

88.96

Miscellaneous expenses not written

-

-

-

-

-

Total

2,538.76

1,918.56

1,575.47

1,299.70

1,156.01

Notes:

Book value of unquoted investments

32.87

777.37

531.01

319.96

578.54

Market value of quoted investments

0.33

0.35

0.36

0.34

1.93

Contingent liabilities

26.23

27.23

21.21

15.81

15.29

Number of equity sharesoutstanding (Lacs)

1359.92

1359.30

1357.81

1357.81

1375.20